Sign in
Not yet recruitingPhase 2/3

Ivarmacitinib Treat PMR

Key facts

Who runs it
Zhejiang University
Where
China6 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 2/3
People taking part
144 people, planned
Starts
1 Dec 2026
Expected to end
30 Dec 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ivarmacitinib
  • Prednisone
Record updated
17 November 2026

Who can take part

Age
50 years to 88 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • patients who fulfilled the 2012ACR/EULAR criteria for PMR;
  • Patients with high activity rheumatic polymyalgia: disease activity score PMR-AS > 10,
  • Adults age 50-88, Weight 45-85Kg,
  • ESR>40mm/h or CRP >50mg/L(5mg/dl),
  • Informed consent

Who cannot take part

  • Patients with previous visual field disorder or single eye dysfunction, cataract patients,
  • Have used biological agents or added azathioprine, FK506 within 1 month before enrollment,
  • Those who have participated in other drug clinical trials within 4 weeks
  • Patients with known allergies to Ivarmacitinib, prednisone or methylprednisolone,
  • Subjects with any severe acute, chronic or recurrent infection (e.g. pneumonia or pyelonephritis, recurrent pneumonia, chronic bronchiectasis, tuberculosis, etc.),
  • Hepatitis B virus carriers or individuals with chronic active hepatitis B or C, other chronic liver diseases, HIV infection,
  • Patients with a history of malignancy who do not meet the following condition (patients with malignant tumors who have been successfully treated for more than 5 years before screening without any evidence of recurrence),
  • Patients with decompensated cardiac insufficiency or severe hypertension or diabetes mellitus, i.e. systolic blood pressure higher than 160mmhg or diastolic blood pressure higher than 100mmhg,
  • Patients with active bleeding and peptic ulcer,
  • Patients with identified giant cell arteritis, systemic lupus erythematosus, rheumatoid arthritis, calcium pyrophosphate deposition (CPPD) arthropathy, and other rheumatic diseases,
  • Patients with abnormal liver function (ALT/AST 2 times higher); Moderate to severe renal impairment (glomerular filtration rate <60); hyperlipidemia not improved by lipid-lowering drugs,
  • For patients with abnormal blood routine, lymphocytes <500/mm3 or ANC <1000/mm3 or HGB < 90g/L,
  • Patients with severe osteoarthritis,
  • Pregnant or lactating women,

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 50 and 88 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the efficacy of the combination of Ivarmacitinib and short-term glucocorticoid induction for remission and rapid discontinuation of glucocorticoids in the treatment of Polymyalgia rheumatica (PMR) , and to compare the differences in the proportion of patients in remission at weeks 24 between the experimental group and control group.

The 2 groups in the trial

  • IvarmacitinibTreatment being tested

    Withdrawal of prednisone within 8 weeks: 15mg daily for 2 weeks, 10mg daily for 4 weeks, 5mg daily for 2 weeks, then discontinue; Take Ivarmacitinib 4mg daily for 24 weeks, then 2mg daily for 28 weeks.

  • PrednisoneExisting treatment, for comparison

    Prednisone 15mg daily was set as the initial treatment of PMR. When improvement was achieved, the dose of Prednisone was reduced to 10mg daily within 4-8 weeks; When remission was achieved, then taper Prednisone gradually by 2.5mg every 10 weeks. Once relapse occurred, the dose increased to the pre-relapse dose.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Ivarmacitinib for Polymyalgia Rheumatica (ESI-PMR): A 52-Week Open-Label, Randomized, Controlled Clinical Trial
Criteria questions
Built from NCT07941778, who can take part
Record updated
17 November 2026